Longevity Summit Dublin 2025

Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Greetings and welcome to the United States Transhumanist Party Virtual
Enlightenment Salon. My name is Jannati stolier Off the second
and I am the Chairman of the US Transhumanist Party.
Here we hold conversations with some of the world's leading
thinkers in longevity, science, technology, philosophy and politics. Like the

(00:21):
philosophers of the Age of Enlightenment, we aim to connect
every field of human endeavor and arrive at new insights
to achieve longer lives, greater rationality, and the progress of
our civilization. Greetings, ladies and gentlemen, and welcome to our
US Transhumanist Party Virtual Enlightenment Salon. Today is Sunday, July sixth,

(00:45):
twenty twenty five, and for me it is Sunday evening
because I am still in Dublin, Ireland, two days after
the conclusion of Longevity sum at Dublin, the fourth instance
of Longevity sum At Dublin. I have been in attendance

(01:06):
at every one of them since the inaugural summit in
twenty twenty two, and of course Longevity sum At Dublin
began as a collaboration between LVF, the Longevity Escape Velocity Foundation,
of which I'm one of the directors and the treasurer

(01:28):
and Longevity Events Limited, which is a company run by
Martin O. D who has done a tremendous amount of
the organizational work for all of the summits. This year
was new in that Martin od and Longevity Events Limited
were essentially the sole and principal organizers of this event.

(01:55):
So it was a bit different at different venue at
the Trinity Business School at Trinity College, Dublin, but robust attendance,
a lot of fascinating presentations, a lot of great people,
including long time participants in the longevity community as well
as some newcomers to it. So joining us today is

(02:20):
our distinguished panel of US Transhumanist Party Officers, members, allies,
and some notable attendees of Longevity sum at Dublin. From
the USTP officers, we have our Director of Visual Art
and current Vice Chairman, art Ramon Garcia and our Director
of Scholarship, doctor Dan Elton, now from among the attendees

(02:44):
of Longevity sum at Dublin. In addition to myself, we
have our friend David Wood of London Futurists. He is
also the executive director of LVF, the Longevity Escape Velocity Foundation,
and we have doctor Jose Cordero, who is our foreign
ambassador in Spain and our technology advisor. Both of them

(03:07):
are regular guests on our Virtual Enlightenment salons. And we
are also about to be joined by our friend Sven
Volts from Belgium.

Speaker 2 (03:20):
He is a.

Speaker 1 (03:22):
Member of Heals, the Healthy Life Extension Society in Europe,
and he actually was a guest on one of my
panels before I became chairman of the US Transhumanist Party,
so he was one of our guests in twenty fifteen.

(03:44):
I know Sven from a long way back, So welcome
to our panelists. Why don't we start with David Wood
because he has some insights as to a few of
the notable presentations that transpired, and then we will go
to Jose Cordero. He has actually some slides from his

(04:08):
presentation that he will share with us today, and then
we'll go to Spend for his insights. At least that's
our tentative schedule unless we have other guests making an appearance.

Speaker 2 (04:21):
But David, please go ahead.

Speaker 3 (04:24):
It's my pleasure, and in case other guests do come in,
please cut me off. I'd just like to highlight a
few of the remarkable talks that I saw, And I
could actually talk about sixty remarkable talks, because there's a
whole bunch of fascinating stuff there. But I'm going to
constrain myself to a smaller number, and I'll start with

(04:44):
a professor who is based in Dublin emm at healing.
She is one of the world's leading researchers into bats.
And what does what do bats have to do with longevity? Well,
it turns out that bats are remarkably long lived for
them a small size. We're used to measuring IQ or
eq whether something called l q a longevity cootient, which

(05:08):
is the expected lifespan divided by the size roughly, because
by and large the smaller organisms are smaller mammals are
at least or birds then they're short of their lives. Well,
bats are. Some species of bats have remarkably long lifespan,
and Emtilan has been studying them and we still don't

(05:30):
know exactly how they manage it despite having their hearts
going thumping away at a great speed. But the one
thing they have is the ability to fight off lots
of viruses. And many of us are afraid of viruses
or bats rather because bats seem to bring viruses to humans,
but on the positive side, they have the ability to

(05:51):
not be defeated by these same viruses, and that's one
thing to learn from them. And another thing to learn
from them is many of them. It seems they're telling
me is don't show. They're telling me to stay the
same size throughout their lives, not all of them. And
it turns out there's not just one species of long
live bat. There are many species of long live bats.
Bats are one of the most successful groups of mammals,

(06:13):
and there are large numbers of different species, and the
likelihood is we can learn lots of different things from
these different bats. So look up Matt Healing. The second
person I want to mention is Jennifer Garrison, who is
the researcher at the Buck and she was one of
a number of professors and speakers who spoke about the

(06:35):
particular aspects of female aging and longevity. And it turns
out there's a whole bunch of things happening in women
or females which are different from aging in males. But
if we understood them better, perhaps we would have insights
into aging all around. She spoke about ovaries, and she said,
we used to think we tend to think of ovaries

(06:56):
as reproductive organs, but it seems they have a much
wider role in the signaling that takes place between all
the organs and women. If you look at the aging
of different organs, most of them have the same sort
of trajectory. They are quite healthy for most of our lives,
and they all go downhill later in life. All overarays
go downhill much faster, but they don't stop altogether. And

(07:20):
so basically, Jennifer Garrison and many others are arguing that
we should be studying this much more, not just for
the sake of women being healthier for longer, but there
are other things we can learn too. Then there's another
angle on reproductive health. And I'm going to refer here
to Utah Lee, who is a fascinating researcher, and he

(07:43):
has access to a different kind of stem cell. We've
all been looking forward to stem cells doing remarkable things
for medicine and longevity. It hasn't quite lived up to
its promise yet. But he was given by his father,
who is renowned surgeon, quite a while ago stem cells

(08:03):
from a different medium well to be precise an ectopic pregnancy.
So when a baby unfortunately, or rather the embryo unfortunately,
gets stuck in the flopian tube, it very quickly stops
being viable and it can grow, and if it's not
stopped in time, it can damn it. It can cause
their mother's death. And at this stage the bundle of

(08:26):
cells is in two parts. There's the part that would
have become the baby and there's the part that would
have become the placenta. And normally all of this is
thrown away, but it turns out that the placenter in
these topic embryos is particularly good for growing stem cells,
and the advantage of this is that there are no
particular ethical quandaries about using it. These are normally all

(08:50):
thrown away the center, but it's a very young pluscenter,
and so the cell sets cells there particular promise. So
yet has been hanging on to this for a long
time until other aspects of the technology are strong enough.
But it seems that there's a whole bunch of different
play therapies that his group is likely to be able

(09:11):
to bring to the market. So stem cells and the
exosomes that often come with them are examples of additive
technologies ways of helping people to live longer by adding
things into bodies. Well, the next two speakers I want
to mention both talked about subtractive technologies. That's things we
can put into the body to subtract aspects of what's

(09:32):
gone wrong in our body. So I want to talk
about nanotics. And if you haven't seen the presentations about
nanotics before given by lou Hawthorne, who is their CEO,
I recommended you spend some time looking at these presentations.
There are some online. They are remarkably engaging. What they
have there is the ability to remove molecules from what's

(09:54):
called the signal om. This is not the genome, it's
not the epigenome, it's not the metabolum. The signal home
is the set of molecules which are used to signal
between different parts of the body. And there's a lot
of molecules which can go past their useful time. They

(10:15):
can be floating in soluble form in the blood and
the causing damage later on. It's a bit like the
immune reaction, you know, when you have inflammation to start
off with. It's good because the body needs to apply
lots of attention to something that's sick on invader. But

(10:36):
if that inflammation goes on too long, it can be
very damaging. It's called inflammaging. Well, in the same way,
there are lots of molecules that need to be removed,
and it's been very hard to remove them up till
now because anything that removes them, any drug that removes them,
often damages the same cells when they are not yet

(10:58):
in the bloodstream. They are to be activated and the
body still needs these membrane based cells. And what blue
Hawthorne and his team have developed are nanautics, and this
sounds a bit like nanotechnology. It's nanosized, little four layer molecules.
It's very clever how they're constructed, and you can program

(11:20):
them so they will remove the soluble versions but leave
their membrane versions alone. And he can tackle lots of
different diseases and also lots of different aspects of aging.
So he has been building up his understanding and his
technology for a number of years and it seems that
he has got more funding than ever before. He's still

(11:41):
looking for more funding, but that was encouraging. Somebody else
who has got fascinating subtractive technology is Matthew O'Connor from cyclarity,
which by the way, was span out from sense some
time ago. And they have also a platform, So nanotics
is one type of platform to remove elements of damage,

(12:04):
but targeting it very precisely well. Once cyclarity. I've got
these particular expertise in something called cyclodextrins. I'm not going
to try and describe a cyclodextrin, I'll surely get it wrong,
but it can be tailored to a very precise geometry
so that it attaches just to one particular molecule that

(12:24):
is causing damage. And like nanautics can be targeted at
many different sources of damage. Also, these cyclodextrins can be
targeted many but the lead target for cyclarity is something
that kills huge numbers of people. It's the cause of
off rosclerosis. That's when there's too much junk accumulates in

(12:45):
our arter RaSE and it's caused by macrophage is not
being able to properly clear certain kinds of cholesterol. And
there's one molecule called seven keyso cholesterol. Well, Matthew Connor
AND's team have come up with cyclodextra and that's precisely
targeted to remove this and this is very good news
because people who have been accumulating this junk in our

(13:09):
art race. We can use statins to slow down the
pace of accumulation, but there's been nothing up to now
to remove it, and so that's very encouraging too. And
in both cases I expect there will be lots of
different solutions coming. But having spoken positively, the last of
the six people I'm going to mention is Andrew Steel.

(13:30):
Andrew still believes passionately in the ability of these technologies
to help undo aging, but he thinks that by default
it's going to take a long time. So he spoke
in the final session along as it happens with Brian Kennedy.
They were anticipating what might happen by twenty thirty five,
and under Steell's forecast is that unless things change significantly,

(13:54):
we're still only going to be making modest progress, probably
by twenty thirty five. On the other hand, he sees
lots of ways in which that progress could speed up.
But in each case, guess what's missing is funding. So
Andrew's presentation when it comes online, I recommend all of
you watch it. He is not just a scientist, he

(14:15):
is an excellent science communicator and Out of many good
presentations that I saw, Andrews was about top of the bunch.
I didn't see all of them, so I apologize for
if I didn't highlight all the great presentations. But Andrew's
presentation says, well, we're probably going to need up to
one hundred billion dollars to be released some stage early,

(14:38):
hopefully in the next ten years, and if we can
do that, we'll have enough to tackle many different hallmarks
of aging and many types of damage simultaneously. Andrew thinks
it's possible that I try addressing one type of damage
might be enough to fix all the other types as well,
but it's unlikely. He thinks we're going to need lots
of different approaches and parallel So one hundred billion dollars

(15:02):
and that's not so much when you look at it
from one point of view, which is there are probably
a billion adults in reasonably well off parts of the world,
and if each such adult had one hundred dollars to give,
we would get up to one hundred billion. So what's
holding us up? And Andrew has created a new institute
called the Long Jevity Institute. You've got to type all

(15:23):
these three words in if you type just longevity Institute,
you'll go to something else altogether, but their Longevity Institute
dot com. There's nothing much there now. But he has
just announced this institute and what they're trying to do
is to come up with policy recommendations to governments to
encourage governments to apply much more funding in this area.

(15:44):
And many other people have said, well, we've got to
have petitions to the governments to encourage them to pay
attention to this field. Will Andrew's trying to, yeah, longevity initiative.
I think it's the Longevity Institute. No, it is called
the Long the Institute. I looked it up earlier. And
Andrew is coming up with the recommendations which will cause

(16:08):
the holders of public postings to make donations. So he
has created this together with a Bulgarian lawyer based in
London called Kamen Scholev. It's a bit too early for
them to say much about it, but I expect he'll
be on a future Franchiumunist Party Virtual and kimin Salen

(16:28):
when he's ready to say more. So it was a
great presentation in terms of here are the possibilities, here's
what's holding up into these possibilities. And with a positive
vision that let's be as smart as possible in finding
a way to talk to political leaders to encourage them
to unleash much more funding and by the way, make
some changes to the regulatory systems as well. So there's

(16:52):
a brief snapshot as to some of the fascinating presentations
which I saw in Dublin.

Speaker 1 (17:00):
Yes, thank you very much, David, and I second your
comment about the desirability of having common shoylive come on
to a future virtual Enlightenment salon. He is a lawyer,
and our audience has expressed an interest in hearing more

(17:20):
presentations from people in the legal profession. But he always
has a very interesting angle with regard to any of
the subjects that he discusses. There exceptionally well researched and
he provides a lot of good factual objective background as
to the subjects that he discusses. So I met him

(17:44):
at Vitalist Bay during the Longevity Policy Conference and I
think he would indeed make an excellent guest in regard
to Cyclarity and Matthew O'Connor. I did connect with him
as well during the summit, and we have scheduled what

(18:05):
will hopefully be a segment where he will be providing
some comments in July, but that is to be fully
determined in the coming weeks. But hopefully sometime by the
end of July, we will have a salon featuring Matthew
O'Connor and Cyclarity. And there's a lot more to say

(18:29):
on each of the topics that you mentioned, David, so
thank you very much. But at this time let us
go to doctor Jose Cordero. Jose, please let us know
what you thought of Longevity Summitt Dublin, and also feel
free to deliver your presentation.

Speaker 4 (18:52):
Yes, thank you very much, and I agree with many
of the things that David was mentioning because those were
our top presentage, of course. And one of the good
things is that there are longevity conferences.

Speaker 5 (19:05):
All over the world.

Speaker 4 (19:06):
Now I personally will be going this year to twenty
conferences in twenty different cities. So it's good because we
need to get to the local publics, to the public
in Ireland, to the public in the USA, to the
public in the United Kingdom, etc.

Speaker 5 (19:23):
Etc. Etc.

Speaker 4 (19:25):
During the Longevity som in Dublin, there were many good presentations.
In fact, there were many many running also in parallel,
so this is the presentation I made in parallel, which
I think should be interesting also for people in the
USA and other parts of the world, because we are
positioned in Madrid as the longevity capital of Europe, which

(19:49):
has been, as you know, the longevity dream, or as
I like to say, immortality, the biggest dream of humanity
since the beginning, as we know in the Epic of
Hell damageands and thousands of years ago in Mesopotamia written
in Kuneiform writing style, the first book ever written by humans.

(20:09):
Also the Book of the Dead in Egypt four thousand
years old, or Emperor Kinshi Juan who built the Terracotta
Army because he also wanted to be in Morta. In
terms of Spain, there is a long tradition of immortality.
In fact, ose I.

Speaker 1 (20:27):
Don't think we see your slides advancing, so the instance
that you've shared is the PowerPoint window rather than the
full screen view there and now we see the Fountain
of youth.

Speaker 5 (20:40):
Okay, thank you.

Speaker 4 (20:42):
So Juan poncele Leone, you know when he went to
the Americans that were discovered or rediscovered by Spain in
fourteen ninety two, he was looking for the fountain of youth,
and many of the other explorers discoverers were looking for immortality.
So this tradition of immortality is also important in Spain.

(21:04):
Spain two thousand years ago, when it was part of
the Roman Empire, was the end of the Roman Empire
to the west, and that is why Spain was called
the country of non plus ultra, which in Latin means
nothing far beyond, because Spain was the end to the
west of the Roman Empire. But then when America was

(21:26):
discovered or rediscovered in fourteen ninety two, the motto the
logo of Spain was changed to plus.

Speaker 5 (21:33):
Ultra plus ultra.

Speaker 4 (21:35):
And now we are trying to make it into longevity
and we say we have to move into vita plus ultra.
And this is the law that I'm pursuing in Spain
with many colleagues, to position in Spain as a longevity
country and Madrid as a longevity capital.

Speaker 1 (21:52):
So while you're not seeing the slides advance unfortunately, I
think you may be advancing them in the full screen
view you but the view that you're sharing is the
PowerPoint interface. So let's see what we can do to
change that. Yes, I think you can manually move them,

(22:15):
but you would have to move them within Yes, within
this interface here, yes.

Speaker 4 (22:21):
Okay, so you see then Madrid, statistically speaking, it is
a reality. Madrid is the muscil on Jevo's city in
the European Union and in Spanish the muscle on Jevl's
country in the European Union. If you look at the numbers,
Madrid is eighty six point one years. These are not

(22:43):
the Spanish numbers. These are European numbers from Eurostat, which
is the statistical center of Europe. And then you can
see other places that have lower life expectancies. But this
is also interesting to compare to the USA. The USA

(23:04):
has the lowest life expectancy among advanced nations, with only
seventy eight now picking back up to seventy nine after COVID.
It's still very much lower than in Europe. So there
are many things to be learned about the European experience,
and particularly the Spanish experience and the Madrid experience. It

(23:27):
is true that there are some other countries. Among larger countries,
only Japan has a larger life expectancy, and then there
are small countries.

Speaker 5 (23:38):
You could name, maybe Hong Kong.

Speaker 4 (23:42):
Switzerland also has a probably longer life expectancy. And in
the Vatican in Rome. In the Vatican they say they
are already immortals, so that is also another thing to consider.
But the trends in Spain keep on going up. There
are many studies that show that in the next twenty
years Spain will overtake Japan and leave behind China and

(24:09):
the USA in terms.

Speaker 5 (24:10):
Of life expectancy.

Speaker 4 (24:12):
That is the reason why I was a candidate for
the European Parliament in the last two elections in two
thousand nineteen and then again in twenty twenty four. And
my goal is that we do something in Europe in
terms of life expectancy, because not only do we have
larger life expectancies than the USA and many other places,

(24:34):
but there is no national or European institute of anti aging.
So my goal was to create the European Anti Aging Agency.
Many of these ideas I had the pleasure to develop
with my friend they would that just spoke and we
wrote a book that came out just before the elections

(24:55):
to the European Parliament that helped to position these ideas.

Speaker 5 (24:59):
The Death of Death.

Speaker 4 (25:01):
And when the book came out, it was immediately number
one and number five simultaneously in Amazon number one in
paper and number five in kindled. This was obviously in Spanish,
but then it has been coming out in many more languages.
We have been donated all the royalties the book rights

(25:22):
to two institutions for the Spanish edition, the SENSE Research
Foundation in the USA and a Spanish organization called.

Speaker 5 (25:30):
A Padrina las Ciencia.

Speaker 4 (25:33):
The book also has the produg of Aubrey de Gray
and the epilogue of my friend Alex Chavoronkov. The book
now is soon going to be in over twenty languages
by next year. It has sometimes different titles in different languages,
but the book is doing very well, especially in the
three top languages of the world, which are Spanish, English

(25:57):
and Chinese. And then again that is why we want
to organize this activity in Madrid, the International Longevity Sawmit.
This will be the second time we organized it. Last
year it was the first time, coinciding with October first.
Why October first, because that is International Longevity Day and

(26:20):
last year we had about three hundred participants. This year
we plan to have hopefully five hundred participants, which will
position our event as the biggest event not only in Spain,
but the second biggest in Europe after the conference in
Copenhagen ard the Aging Research and drug Discovery. We will

(26:42):
do it in a very important place in the College
of Medical Doctors of Spain. This is a very important institution.
It compiles all the medical doctors of Spain and they
are fifty five thousand medical doctors in Spain.

Speaker 5 (26:58):
That is a large, very important number.

Speaker 4 (27:01):
And we will do it in the most beautiful Amphitheater
of Spain, Classical Amphitheater, which is where the Nobel Prize
winner from Spain in Medicine, Santiago ramon Ikahal gave his lectures.
A beautiful place, a beautiful speakers. We are bringing speakers

(27:23):
from all over the world, beginning also with Madrid. The
Mayor of Madrid will be speaking at the conference, and
not only because Madrid is the most longeveals city in
the European Union, but because we need to push this
idea in Spain, in Europe and throughout the world that
it is possible to have longer life expectancies. And we

(27:45):
are going to declare Madrid as a real blue zone
or a blue zone two point zero, because the blue
zones now are not real, they.

Speaker 5 (27:55):
Are basically marketing.

Speaker 4 (27:57):
There are a few things which are important, of course,
the diet, exercise, family relations, all of those things that
we have for example in Spain or in Madrid. But
it is important to be able to scientifically prove if
this is so, and we are going to be presenting
three top studies about why Spain and Madrid have the

(28:19):
longest expectancy in Europe. One by the top management consulting
company McKinsey, actually the McKinsey Health Institute that takes Madrid
as the example of a longevos city. Also by the
National Science Foundation of Spain, which is the top scientific
institution in Spain, and also the Royal Academy of Medicine Spain,

(28:42):
as you know, has top scientists like Juan Carlos Is
with Sua Belmonte, who was before one of the directors
of the Salt Institute in La Joya, San Diego, California,
and now he's part of Altoslabs. One of the investors,
as you know, is Jeff Bezos. By the way, Jeff

(29:04):
Bezos was in Madrid for his bachelor's party, and we
will have our party, the Longevity Party, in the same
place where Jeff Bezos had his bachelor party. We have
been bringing many top people scientists, like we brought also
a couple of years ago Shinya Yamanaka for another special

(29:25):
activity with the College of Medical Doctors in Spain, and
we will be talking about the things coming up, like
I'm very excited about the ex prize Foundation and Evolution
Price that my friend Peter Diamand is announced in a
read in Saudi Arabia in November of twenty twenty three.

(29:46):
There are over six hundred teams participating in this out
of which five are Spanish and one of the top
forty that is the highest ranking as of now, one
of the top forty is a Spanish team, so we
are very proud to have Spanish teams. We also want
to invite you to come to Madrid and to see

(30:08):
the country which is beautiful. Spain, together with Italy and
together with China, are the top three countries in UNESCO
World Heritage Sites, and many of these sites are around Madrid,
so we want you to come with us to see
the beauties of Spain and to understand why we need
to live longer to see these places to learn from

(30:30):
other cultures. For example, we will see the Roman Aquaedu
of Segovia. Actually my mother is from Segovia, so I'm
very proud. This is the biggest, longest, oldest Roman aquaduct
still standing up over two thousand in Segovia. We will
also see the beautiful al Castle, the Segovia, the Castle

(30:53):
of Segovia. There was the inspiration for Nouin sch Einstein
in Bavaria in Germany and for the Disney and Castle
in Disneyland. If you have been to Disneyland anyway. The
conference will be fantastic. We will have a lot of
side activities as well. We will have fantastic Spanish food,
Mediterranean diet. We will launch the Madrid Longevity Declaration, explaining

(31:18):
why Madrid is the leading city in Europe and in
Spain the leading country. We will have also films documentaries
like Longevity Hackers that we actually filmed part of it
in the medical college in Madrid, since I am an
advisor to that film and one of the people interviewed.
And we will have a rally. We will have a

(31:40):
march throughout Madrid. We will begin at the famous City
Hall of Spain, which is where Real Madrid, the best
football team, the best soccer team in the world, celebrates
continuously and we will be carrying flags, We will have balloons,
we will have banners, we will have t shirts, teachers

(32:00):
saying and stop aging in Spanish. Of course aging is
long in Spanish and the hesibiento, but we will be
talking about the stop and thejcimiento in the city Hall,
in the Government of Spain, in the Congress of Spain,
and also in the European Parliament.

Speaker 5 (32:21):
Offices in Spain.

Speaker 4 (32:23):
So we are very proud about taking public opinion to
understand how important longevity is. We will also have prices.
We will have the Sibelius price. Sibelius is the symbol
of Madrid and she was a Turkish goddess twenty thousand
years ago, a goddess from Turkey, and she is a

(32:45):
symbol of fecunity at longevity. So we will have prices.
Like last year, we also gave a posthumous award to
Maria Branias, who was the oldest living person in the
world until she died last year just before our conference.
She was going to speak virtually in our conference, but
sadly she died at the age of one hundred and

(33:08):
seventeen days and one hundred and sixty No one hundred
and seventeen years and one hundred and sixty eight days anyway,
so we will have the Civilis Longevity words in Madrid.
We have had incredible media coverage. We were in all
the media in Spain and also internationally in many different publications.

Speaker 5 (33:28):
So we are very proud and we taught.

Speaker 4 (33:31):
We have incredible responsor institutions like the top institutions of
Spain that I mentioned, the College of Medical Doctors, the
Royal Academy of Medicine of Spain, the Government of Madrid,
the Innovation Center of Madrid, and we have an incredible
scientific committee led by George. George who will be one

(33:53):
of our speakers, and I think everybody knows Church, so
no explanation needed for him him, And so all of
you are welcome for the UNESCO World Heritage Visits September
twenteen and thirteen, and for the Longevity Summit October first
and second.

Speaker 5 (34:10):
So as I like to say to all my friends,
live long and prosper.

Speaker 1 (34:17):
All right, thank you Jose and of course we should
all live long and prosper. And for those of you
who would like to attend Transvision Madrid, here again is
the website Transvisionmadrid dot com. Let's show Jose with the
stop aging shirt in Spain.

Speaker 2 (34:36):
So here he is.

Speaker 1 (34:37):
And you had balloons that also had this design as well,
and you had the flag.

Speaker 2 (34:44):
Of Spain with you.

Speaker 1 (34:46):
You brought it on our let's say, extracurricular excursions around
town as well. Oh, we're going to see the balloon. Excellent, excellent, Yes,
So these have been quite popular in Spain during the
longevity marches that you have done. They've attracted a lot

(35:08):
of attention, a lot of interest. You've said in a
previous presentation that even the police have joined in the
marches with you. So I look forward to seeing what
you're able to achieve there this year. And we have
some good words from our attendees. So first of all,

(35:30):
Alberto Aparicio, who was also there at the summit, writes
great panelists and coverage of the summit. Luis has some
words of praise for David Wood keeping transhumanism alive across
the Pond. And then with regard to the Death of

(35:51):
Death book, Mike Lausine writes, well done Jose and David.
Jason Geringer likes the theater in which Transision Madrid will
be held and Michael Zine agrees that was a beautiful theater,
great architecture. So thank you to our audience for these comments,
and we will discuss more as the salon progresses. Now,

(36:14):
I would like to invite then Vulteris to provide his
impressions of the twenty twenty five Longevity Summer Dublin.

Speaker 6 (36:24):
Okay, hello everyone, can you see my slights?

Speaker 2 (36:29):
Yes, just a moment, Yes, here it is.

Speaker 6 (36:32):
Yes, okay, So yeah, I just took a few pictures
from the conference and I put them in a PowerPoint presentation.
So yeah, the quality is maybe not the best, but
we have to do with what we have. How can
I start After the amazing samway that David already gave us,
he touched upon many of the great lectures that were

(36:53):
given that I would also like to highlight, For example,
Emma Dieling's lecture.

Speaker 7 (36:58):
I was not familiar with her before.

Speaker 6 (37:00):
She presented a lot of unpublished data, and you know,
there's nothing greater when you are at a conference when
unpublished data get presented, because published data you can read
at home, but unpublished data you obviously can't read. So
that's always great to learn new things. I saw multiple
lectures that I had seen before, for example in Berlin

(37:23):
last year, but of course I were updates. So those
were the lectures of Lou Howton, W. Kiproff and Ok O'Connor.
I had seen those before, but I was using them
and that was exciting news.

Speaker 8 (37:39):
Uh.

Speaker 6 (37:40):
And one other thing we learned that the conference is
what is here on the slide. So you see here
an aging clock, the immunology pace clock. And what was
pointed out here is that you have to be careful
to look at trajectories and not just look at in
diffidgual time points. So here in red you see, for example,

(38:02):
someone who started with a younger biological age, but as
time progressed, that person aged fast, while here you see
someone who started with an older biologically aid, but actually
it's slightly declined over time. So the trajectory is very
important rather than looking at an individual time point. And

(38:24):
there were multiple lectures on various clocks and ways of
measuring epigenetic age of biological age.

Speaker 7 (38:32):
So here this was one of the slides that was
put up.

Speaker 6 (38:36):
Tom Cruise at sixty vasus Faulkilmer at sixty two both
played in the famous movie together. Since then, val has
died and Tom is still doing quite well, so two
people of about the same age chronologically, but with a
very big difference in health outcomes. And one of the

(38:59):
clocks that was extensively discussed in the conference was this
one that was developed by young Huber, and what they
did is they took sixty clinical parameters to demographics, but
also things about the blot work croup of people and

(39:20):
they made a biological clock from that, and then they
use the principal component analysis, which is a mathematical technique
that allows you to reduce the dimensionality of data and
you get all of these principal components out of it,
and different principal components are associated with different diseases, so

(39:45):
this means it's a clock where you don't just get
a single number out you know you're biologically forty or whatever,
but you actually get more information about your specific disease risk.
And in fact, there was an all there from his collaborate,
uh the name is Canton. I hope that correctly, and

(40:12):
he really showed the clinical application of this clock where
he applied it to real patients and for example, there
was one patient that had a very high principal component.
Was it the first one or what define it was
one of them which was known to be associated with stroke,

(40:33):
and indeed that person died from stroke. And that person
was also biologically way older then she was chronologically uh
and and indeed she was having a very bad health
and died very soon after the measurements. So they showed
also that this clock, uh, this lineage two clock has

(40:55):
very so this is a rock curve and basically the
higher it is, the more rectangular shape it is. So
this is ideal. The better the clock is, and the
clock is better than the other ones that are shown here,
so very great. Then there was also Albid great lecture

(41:16):
and he presented the data on the Roberts Most Rejuvenation trial.
I don't need to tell you about those data because
I have all been on Facebook, so I think everyone
probably has seen them by now. But they are all
hoping to set up the rejuvenation the Roberts Most Resugnation
Teken twile that will be including all of these types

(41:38):
of interventions, so quite a lot more than in the
first one. And they are looking for five to six
million dollars of funding to fund this research. There was
also an update from the Dock Aging Project by Matt Kimberlain. Sadly,
the grant for the continuation of this file was not

(41:59):
really new, but they are submitting a new grant proposal,
and let's have our fingers crossed that they really get this,
because I think this is really great research.

Speaker 7 (42:11):
Dogs are a lot.

Speaker 6 (42:12):
More clothes to humans than even mynor so this is
very relevant research. And so yeah, what can I say else? Oh, yeah,
of course, But David already mentioned it is the amazing
lecture that Andrew Steele gave, and he's really a person
who is very capable of inspiring people and drumming up

(42:35):
enthusiasm to get off of butts and get to work,
even though he was kind of skeptical because of the
lack of urgency among many people to have to do
something about aging and yet to close. But again this
was also previously mentioned already. There were several one at

(42:59):
the first day of the conference, the pre conference they
actually see and then there was a session within the conference,
both devoted to female health and it's a quite under
studied area of research, and we know from many interventions
that they show sex or specific effects. So if you

(43:22):
look at the IP the Intervention Stesting Program, there are
multiple interventions that are working in males but not in females,
or interventions at work in females but not in males. Already,
effect size of the intervention is quite different between sexes.
So certainly we know about the situation in the United

(43:44):
States where they are actually going back and they are
removing the need of studying sex effects on outcomes in
clinical trials. And I hope they reconsider that because it's
the very important Thank.

Speaker 2 (43:59):
You, yes, thank you very much.

Speaker 1 (44:02):
Then I appreciate your presentation and overview of the some
of the key speakers and some of the key ideas.

Speaker 2 (44:15):
That were presented at the summit.

Speaker 1 (44:18):
I will add the Jennifer Garrison, whom David had mentioned,
also spoke extensively about the scope and extent of harm
that cuts to federal funding of scientific research, particularly at
the National Institutes of Health, are inflicting. Indeed, she had

(44:42):
a slide where she mentioned essentially algorithmic approaches, very crude
algorithmic approaches toward denying grant applications and rescinding already given
approval for grants using essentially certain keywords that are banned,

(45:05):
and I noted in the Q and A one of
the phrases that was banned was evidence based.

Speaker 2 (45:14):
So it seems that.

Speaker 1 (45:16):
The cuts are so sweeping that any proposal that has
a mention of anything evidence based in it is on
the chopping block. And it was discussed that NIH funding
in the United States is by far the predominant source
of funding for scientific research. It dwarfs private industry funding,

(45:42):
philanthropic funding, even funding from large foundations, and that in
itself may be a suboptimal situation in.

Speaker 2 (45:51):
That a lot of researchers are.

Speaker 1 (45:53):
Essentially dependent on the whims of the political process now
and when a new faction comes into power, their research
projects are in jeopardy, including the research projects that have
already been initiated. It is actually why I have long
emphasized while government funding of research comes with strings attached,

(46:17):
and one needs to be very careful about those strings
attached because the nature of those strings too can change
over time and can change quite dramatically. So that's an
unfortunate situation. I think it has a lot of longevity
researchers on edge right now, and I definitely gathered a

(46:37):
sense of this now, Dan, do you have any thoughts
on this?

Speaker 8 (46:43):
Yeah, Well, you guys can hear me, right, Yeah, I
agree with and everything you just said, and I can
talk more about what's going on in NIH.

Speaker 9 (46:54):
People are interested.

Speaker 8 (46:55):
But I was actually interested in learning a little more
about the dog gauging project because I remember a year
or two about it, maybe six months ago.

Speaker 9 (47:03):
Or a year ago. They were.

Speaker 8 (47:06):
It sounded like they were actually looking for private donations.

Speaker 2 (47:13):
Yes, so the NIH.

Speaker 1 (47:15):
My understanding is the NIH had not renewed the grant
for the dog aging project, and this happened in twenty
twenty three. I remember Aubrey was posting about it on
Twitter as well, noting the tragedy and travesty of this
in his view. And it seems that there was some

(47:38):
philanthropic funding that was found as a bridge for the
dog aging project. So currently it is privately funded. It continues.
But my impression of Matt Caberline's remarks is this was
intended to be temporary. This was intended to keep the
lights on, so to speak. And they are applying for

(47:59):
another their NIH grant now with hopes that they will
be renewed for a five year period. So these grants
apparently are for five years. And David also points out
one of the many words whose presence on a grand
application will cause it to be rejected is measles, and

(48:21):
I think we know whose influence that is. So that's
such an unfortunate situation that this is the crude way
in which grants are being rejected.

Speaker 2 (48:32):
But hopefully that answers your question, Dan.

Speaker 8 (48:36):
Yeah, No, it's yeah, that their grants are getting canceled
left and right, and there's very severe budget cuts that
have been proposed, I think up to forty percent.

Speaker 9 (48:48):
And normally, you know, normally you would say, well that.

Speaker 8 (48:56):
You know, the Congress usually overrides whatever the president proposes,
and usually the president doesn't really get what they proposed.
But we just saw a bill that was past, the
so called Big Beautiful Bill, that was largely dictated by Trump,
and so the Republicans seem to just be falling in mind.

(49:20):
So it's a bit scary. And also what surprised me
is they're also looking to cut NASA by up to
fifty percent, which is crazy because NASA's both NIH and
NASA are two of the most popular agencies among the public.

Speaker 1 (49:39):
Yes, and NIH and NASA are both agencies that bring
about the greatest return for each dollar spent. It's a
return of many multiples, So I think it's a very
short sighted and ill founded decision. But Dan, please feel

(50:00):
free to say anything else you have on this.

Speaker 8 (50:04):
The only I mean the other thing was the way
they did the cuts was very like irrational because they
basically just cut across the board and they had a
goal to centralize a lot of the HR staff who
were in different institutes, but they basically just cut all
the all.

Speaker 9 (50:23):
The HR staff before this centralized HR had been set up.

Speaker 8 (50:30):
So one of the big issues in ni H is
it's it's very hard to do anything like like hiring
or getting travel funding approved.

Speaker 2 (50:41):
Or.

Speaker 8 (50:44):
Getting like uh uh, getting funding for your you know,
lab equipment, because they're just there's no staff to process anything.

Speaker 2 (50:55):
Indeed, and there were there were.

Speaker 8 (50:58):
Also some crazy things that happened at the National Institute
of Aging, like apparently Luigi Ferrucci got an email saying
he was fired.

Speaker 9 (51:11):
And then like they rescinded it like the next day
or something.

Speaker 1 (51:14):
So yeah, yes, there have been a lot of firings
and recisions at the federal government because of the rather
thoughtlessly enacted DOGE, the so called Department of Government Efficiency,
which itself seems to have floundered, and a lot of

(51:34):
those cuts have been reversed because they were cutting really
essential personnel, like people who were managing the safety of
the nuclear weapons stockpile or the Ebola response, or air
traffic controllers who are already in woefully short supply. But
I can fully identify with your comments about the problems

(51:59):
that arise with excessive centralization of HR functions because the
most qualified individuals to make hiring decisions are those who
will be working with the people who get hired, and therefore,
the less centralized the HR function is, the more autonomy

(52:19):
actual managers within agencies have to hire people, the easier
it would be to find qualified people, because those who
are closer to the work know what the work entails
and know what kinds of skill sets are needed. The
HR people have no idea essentially, I.

Speaker 9 (52:41):
Haven't heard that.

Speaker 8 (52:42):
I mean, I think generally the HR people just assist
with crossing a lot of paperwork, and most people have
talked to NIH agree that centralizing the HR and centralizing
the IT staff was actually a good idea, just disagree
with how it's being done.

Speaker 3 (53:02):
So that's why.

Speaker 1 (53:05):
Yeah, Yes, there is a risk though that there would
be people who essentially approach the function as a kind
of check the box exercise, and they may especially be
overly rigid in how they enforce the qualifications for particular positions.

Speaker 8 (53:25):
So they are they are they are enforcing more rules,
like right now we an h staff can hire supposedly
you can hire post docs. I've heard it's difficult, but
you can hire post docs, but they can only be
US citizens right now.

Speaker 9 (53:43):
And uh, and there's.

Speaker 8 (53:46):
Different rules that that keep coming down that are that
are basically being dictated from you know, the highest levels.
So there's more, there's more sort of micromanagement and rules
coming down. Then, say, like the first Trump administration, they're
definitely centralizing control of.

Speaker 9 (54:08):
A lot of things.

Speaker 2 (54:11):
Yes, that is unfortunate, so I.

Speaker 10 (54:14):
Yeah, So Alberto Paricio wrights the He concurs the cuts
in federal funding are concerning for biotechnology and for longevity
as a whole.

Speaker 1 (54:29):
David Sinclair's lab in Harvard was deprived from all federal funding,
and David Sinclair had made that announcement on Twitter as well,
So they are essentially having to suspend research projects that
were ongoing unfortunately. And then Luisa Royo notes the private

(54:54):
market may not be able to make up for all
of these cuts. That is the worry right now, because
the other our sources of funding are let's say, much
less abundant than the NIH grants work.

Speaker 8 (55:08):
What we need, sorry, what we need is more basic research,
and I think private I'm not sure private funded. Generally,
private funding is mostly for stuff with a more immediate return,
for you know, file check startups and stuff. So I
talked to actually Rainie uh this woman and Rainie Ramani.

Speaker 9 (55:32):
She has a they have a book coming out.

Speaker 2 (55:36):
On uh.

Speaker 8 (55:39):
I don't want to say the title because they're still
finalizing it. But one of the big points is that.

Speaker 9 (55:47):
Private funding just isn't enough we need.

Speaker 8 (55:50):
We need a lot, a lot of public funding, especially
for the basic aging biology research.

Speaker 1 (55:59):
Yes, certainly it is not a good idea and it
does not help anyone to have the prior funding commitments
essentially yanked out from under those researchers. So even those
who would favor privatization of these functions, such as ein

(56:21):
Rand when she wrote about the subject in nineteen sixty two,
would if their sensible support a gradual kind of transition.
So she had a passage where she was asked, essentially,
what would she do if you were president of the
United States in terms of transitioning the economy from one

(56:42):
with heavy government intervention to more of a lais a
faire economy. And she said, well, she would decontrol gradually,
because so many people's plans, including those of people in
the private sector, are dependent on the current government programs,
the current rules, and you can't just suddenly end them
and expect that people would instantaneously adjust. There are a

(57:07):
lot of projects in progress that very understandably were dependent
on these funds, are dependent on the current structures. So
the way in which it happened, the sudden and arbitrary
nature of it, is unfortunately going to do a lot
of damage. Alberto Aparisio rights, we're living a war on science,

(57:30):
very concerning, especially as other countries will continue to make
progress like China.

Speaker 2 (57:35):
Now.

Speaker 1 (57:35):
Jason Geringer has made some comments that actually relate to
a lot of the topics that we're discussed at the
Longevity Summit. He writes, on the plus side, a lot
of this AI research has been coming out in an
open source manner.

Speaker 2 (57:53):
Once the cat is out of the bag, it's out.
We can make agents do research. Now.

Speaker 1 (57:58):
The whole acceleration idea with LV is the same as
the AI acceleration idea. Once it starts programming itself, you
don't have to do much anymore. Once we can get
AI doing it, we may not need all that stuff.
He says, he's being optimistic, but he also thinks this
is realistic because the acceleration of intelligence is still going
to happen. And he notes though he knows it seems

(58:20):
like intelligence has been going backward recently. Human intelligence. That
is our human stupidity, as Jose would put it. But
AI was indeed discussed extensively at the Longevity Summit, So
I would invite those who were in attendance to comment
on the range of perspectives as well as your own
views on how AI is going to affect the prospects

(58:43):
for longevity research going forward.

Speaker 6 (58:46):
Well, if I may make a small more concerning the funding.
So one of the great things that and Steele is
he broke down the funding for research, and the NIE
is even by the American taxpayer rue dollar thirty cents
per pose. So that's the full amount that each American

(59:08):
person each year gives for what is basically killing almost
ninety percent of the population. And that's just insane in
my opinion. Yes, aging, it's not even a cup of coffee.

Speaker 2 (59:24):
Right right.

Speaker 1 (59:26):
Aging research was already disproportionately underfunded prior to this, and
now unfortunately even more so, especially since the National Institute
on Aging is an institution that seems to be on.

Speaker 2 (59:40):
Its way out.

Speaker 1 (59:41):
It was already under attack by certain members of Congress
prior to these cuts, so it's a troubling development. David,
I know you have some thoughts about AI and scaling.

Speaker 3 (59:56):
Yes, so let me pick up a few of the
very interesting of discussion. A couple of the speakers both
talked about AI and the possibilities for AI to accelerate
dramatically the progress with longevity, and both of them were
quite skeptical about it, and referring to both Andrew Steel

(01:00:17):
and Opray degree and both of them said, you know,
these breakthroughs that AI has made in biology has been
dependent upon collecting data, and unless there is data collected first,
it's hard for an AI to work out the new insight.
So Andrew Steel pointed out there had been a large,

(01:00:40):
publicly funded initiative to collect the structures of some of
the proteins. This was the famous PDB, the protein data bank,
and it had started very slowly and it took a
long long time, over many decades, and only when enough
of that had been worked out by painstaking methods such

(01:01:01):
as X ray diffraction and so on, that was allowed
the much faster progress to be made by the AI
of alpha fold. But unless the data is collected, you
can't do this, as I had at one of did
Conel's say events, before you can join the dots, you've

(01:01:23):
got to collect the dots, and so this is what
needs to be done. So both Aubrey and Andrew stealing
the various ways are optimistic and due cost, the AI
will help, but not until various biological experiments have been done,
and in particular the experiments to find out does this
damage repair mechanism actually work in different animals? And you

(01:01:43):
can't work out in advance unless you've got a complete
model of biology. Demis Hassebus does look forward to the
time when we've got a complete, reliable model of an
entire cell. But this isn't going to come straight away.
It's who knows how long it's going to take to
get There is one method of scaling things up, but
it's not the only method, and I can speak a

(01:02:07):
little bit more to answer a question that Mike Lausine
put in earlier, which is, how are these remarkable technologies
which were spoken about in various presentations, how are they
going to come down in price? And AI might be
part of the solution, but there are other things that's
going to bring it down. And the first thing that's
going to bring down the cost is scale. When you're
only manufacturing something for a very small number of people,

(01:02:30):
it is expensive. But when you do it for much
larger numbers of people, there is a famous law sounds
a bit like most law. I forget what it's actually called.
But as you manufacture and larger and larger amounts, you
learn clever ways to do it better. And so it's
something like this cost comes down as you do it

(01:02:52):
more often. But still there is a risk, Well, what's
going to make people scale this up? By the way
that you can see this in the declining cost co
for solar conductors and solar energy, it has come down
much faster than most forecasters predicted because it's now in
much larger scale. But even in that case, how did

(01:03:14):
the solar manufacturers scale up? They needed government assurances and
government subsidies assurance, government assurances that if things were produced
in scale and they worked, then the government would guarantee
certain volumes. And Aubrey degree has a great way of
explaining this, and he refers to what he said, ironically,

(01:03:36):
is perhaps the best thing this ever happened to longevity.
Wait for it, it's COVID. How on earth could COVID
be the best thing that's ever happened to longevity. Well,
COVID shows that when people really have their minds put
into our crisis, we are capable of doing things much
faster than was previously expected. So before COVID, the fastest
that any virus, any vaccine for a coronavirus had taken

(01:04:00):
ten years to do it, and any other vaccine for
another thing it had taken at least three years. Now
with Project Warp Speed, there was a focus as never before,
not just on developing the individual vactionins, but ensuring they
could be scaled up, that all the different problems that
would emerge, people were thinking about them in advance. So

(01:04:21):
one of the vaccines needed to be stored at a
lower temperature then normal glass could cope with. And so
another part of the Project Warp looked at ways in
which the best glass manufacturers, I think it's cornering glass.
They were able to produce a variant that would work
up the sufficiently low temperature, and they walked up the
logistics of getting this distributed all over the country and

(01:04:43):
who did they use to do the distribution. They turned
to their best private companies for doing distribution, like DHL
and FedEx. So they had the whole thing lined up
so scale, backed by government assurances that if something is good,
they will underwrite the costs that get there. And as
she has more people working in this, particularly in a

(01:05:05):
competitive environment, there is more incentive to be innovative, and
so innovation will bring down the cost as well. Provided again,
there are plenty of different approaches that are being tackled.
And this comes back to the question, well how is
this going to be funded? Because for all these people
that are working here, you need the funding. And I
want to refer here to the chart that Andrew Steel showed,

(01:05:28):
because it didn't just show here's what's being spent miniscule
amounts on research into aging. He also showed here are
other things where we are spending much more money. And
he said, well, we're spending all this money on this,
and all this money on this, and the thing that
costs much more money was treating people who were chronically
ill of the diseases which are age related. We spend

(01:05:51):
enormous amounts on that, hundreds and thousands of times as much.
So the argument that Round the Steel proposes to take
to the politicians is various ways to say, look, you
just need to invest a small fraction of that huge
amount of money and you will have the potential of
having huge savings in what you're spending. So we need
to put some money in. And absolutely it needs to

(01:06:14):
be publicly sourced, because private investors will private donuts are
never going to come up with enough. But when you
can do that, then you can trigger this ecosystem of
lots of clever humans, lots of different approaches around the world.
And yes, you can use AI to accelerate things too,
but without funding, it's going to go slowly. Hence, the

(01:06:34):
most important thing is to make the case for funding
in a way that the various politicians can respect and understand.
That's how we'll get the costs down. After all, I
remember when we were talking about how much is the
coronavirus vactions, how much are they going to cost. Initially
people were afraid, well, it's only going to be for

(01:06:54):
the wealthy, only for the wealthy countries, And the cost
was brought down law for all the reasons I've mentioned,
the scaling, and also government subsidies, and it was enlightened
government subsidies because if you spend a little bit of
money to vaccinate people, you don't need to spend anything
like so much money dealing with people, dealing with people
when they are chronically ill, deeply ill as a result.

(01:07:18):
So these are some of my observations. AI is part
of the solution, but it is not the whole solution,
and we must avoid a rather unfortunate tendency, which is
that many people with money are just investing in AI
thinking that AI is going to solve everything. Instead, we
need to keep on doing the biotech experiments, wet lab experiments,
actually trying damage to pair mechanisms on different mammals, the

(01:07:42):
mice and the dogs, and what Matt Cablin's doing with
his dog aging project is absolutely fundamental and we must
find a way to keep that going. By the way,
that project is funded a lot by the owners of
the dogs. People love looking after the dogs, a lot
of the costs cement by the owners of each dog,

(01:08:02):
but that's not going to be enough to do some
of the other detailed testing, so we must get this
funded by other means.

Speaker 1 (01:08:11):
Yes, indeed, thank you very much, David, and I completely
agree with you and Aubrey about the importance of the
wet lab experiments.

Speaker 2 (01:08:20):
The fact is, no matter what the advances.

Speaker 1 (01:08:23):
In AI are, until the AI becomes embodied and essentially
exists in the forms of androids who have great manual dexterity,
who can go into the labs and do the research themselves,
we're going to need human researchers to do studies in
the lab and gather empirical data for the AI to analyze,

(01:08:47):
because the AI tools can be great for analytical purposes,
but they need the raw data from the external reality.
They have no way of getting the data themselves without
the at lab experiments. So that's a really important point,
and it seems Mike Lauzine is in agreement as well.

(01:09:09):
Alberto Aparicio agrees with your comments David. In particular, he
states that Aubrey's referral to COVID was a great moment
of the summit. Make aging the new COVID. Mike Lusine writes,
if we get something like COVID nineteen again, there will
be far more people who died in the last time,
very scary and sad. Well, interestingly enough, though, what's very

(01:09:31):
scary and sad is right now, far far more people
die of aging than died of COVID in particular, and
even those who died of COVID had their mortality risks
greatly increased by biological aging. So we are already living

(01:09:51):
in this reality. The question is how do we get
the public to recognize this and recognize the moral imperative
of combating it. So now, Jose, please go ahead with
your remarks.

Speaker 4 (01:10:08):
Yes, this is a fascinating discussion, and I loved all
the comments also made by is then done. That spoke
also very important points, and I have a few a
few things to say. First, David, the correct website of
Andrew Stills is the Longevity Initiative dot org. The Longevity Initiative,

(01:10:32):
It's not the Longevity Institute.

Speaker 5 (01:10:33):
It's different. One thing.

Speaker 4 (01:10:35):
The other thing about Madrid is that, uh, those who
cannot come in person, we are also going to be
a streaming live. We are going to be broadcasting from
Madrid to the world in both languages, in English and
the Spanish. The conference will be mostly in English, but
there will be a few presentations that will be translated,

(01:10:57):
uh well, from Spanish to English. Because the Mayor of Madrid,
he will speak in Spanish as his public position requires.
As the mayor of Madrid, the capital of Spain and
the Spanish speaking world, he is forced to speak in Spanish,
so he will be translated into English. But all the

(01:11:17):
other speakers really will be mostly basically in English, and
there will be translation into Spanish, so that you know
that if you cannot come to Madrid, you can join
us virtually. I have a few other comments than what
you said is very interesting, but also we have to
look at maybe some positive science like Mayama Mater. MIT

(01:11:41):
just published MIT Technology Review where they have a special
article about Jim O'Neill. So, Jim O'Neill that many of
you know has been involved for a long time in longevity,
is now the second person in command in the agehas
So I think this could be very positive. Of course,

(01:12:04):
we don't know what will happen, but I think this
is very positive. So I try to look within the
problems where are the opportunities. Also when Sven said that
it is only a cup of coffee, that is true,
that is for our US friends. But vain, what are
you doing yourself because in Belgium is not even done.

(01:12:26):
In Belgium is not even that. So don't complain about
our US friends when in Belgium is not even done.
That is why I run for politics, because this has
to be a fundamental issue in Spain, in Belgium, in Europe,
because we don't have anything like the National Institute on Aging,

(01:12:47):
and we should because Europe is much older, it's aging faster,
and the pyramid has already inverted. The demographic pyramid. It's
already like this, very few children and lots of old people.
So we need to revert that. And for that we
cannot blame it on the USA, not at all. We
should blame it on ourselves. That is why we have

(01:13:10):
to be very proactive ourselves, and that is why I
run for politics, to bring these issues to the public.
I think this is fundamental. Also, I love the phrase.
I also retweeted it about over the grade that we
should make aging the new covin as Alberto A Parisio
also mentioned.

Speaker 5 (01:13:30):
I sent that to several groups.

Speaker 4 (01:13:32):
I think it's fantastic because we need another Manhattan.

Speaker 5 (01:13:35):
Project for aging. That is what we need.

Speaker 4 (01:13:40):
About Andrew still, I also talked to him after his presentation,
which was really fantastic, and he's a great speaker with
a lot of knowledge. But my view is different in
terms of the money, and I told him very clearly
he talks about one hundred billion dollars from the government, No,
that is not the solution. We should have one hundred

(01:14:01):
billion dollars from the private sector. And I will give
you the example of the X Price Foundation. The ex
Rice Foundation, with this healthspan price of one hundred million dollars,
already got over six hundred teams participating on biological rejuvenation
by twenty thirty with just one hundred million dollars, over

(01:14:26):
six hundred teams all over the world, including the Spanish teams,
British teams, I imagine, Belgian teams, and of course many
teams from the USA, Canada and other parts.

Speaker 5 (01:14:38):
Of the world.

Speaker 4 (01:14:38):
So I told Andrew Andrew what we need is to
have the X price not for one hundred million, but
for a billion or for one hundred billion. This will
really increase the creativity of everybody, not just governments, universities,
Start Times pharmaceutical company is a hospitals, clinics, everything. This

(01:15:04):
is what the X price has brought with only one
hundred million dollars. So imagine if it was a billion
dollars or one hundred billion dollars, as Andrew Steel was mentioning.
So anyway, that was my comment to Andrew Andrew Steel.
And now I'm also very excited about AI. As David

(01:15:26):
Wood mentioned, AI is not the solution, but it is
very important, and I'm very excited also about what is
happening in AI. For example, deep Mind announced Alpha Genome.
Alpha Genome is going to be very fascinating, and then
miss Hassavis, the winner of the Nobel Prize twenty twenty

(01:15:47):
four in chemistry. Then Miss Hassavis deep Mind Google, he
created this other company called Isomorphic Labs with the goal
of using AI to cure all this all these this
is really fascinating. Of course, it is not the solution,
but it is a big part of it. And in

(01:16:09):
that same line of AI, also Mark Suckenberg and his
foundation with his wife Priscilla Chan, they have announced that
they are using AI to understand how all sales work,
how all organs work, how all organisms work using AI.
Of course this is a huge project, but I think

(01:16:31):
this is very important. So the Chance Suckenberg Foundation is
doing incredible work also on AI from a different point
of view that what Google is doing with Alpha Genome
or deep Mind with isomorphic labs. But anyway, so I
am really excited about AI. It will help to accelerate things.

(01:16:53):
And even more, if we had an exprice of one
hundred billion dollars, that would really change. So as then,
put your cop of coffee to the X Prize. I
got drink to the X Prize for one hundred billions.
That would give us rejuvenation very quickly.

Speaker 1 (01:17:12):
Yes, well, thank you very much Jose for that note
of optimism. I definitely hope that all of the initiatives
you mentioned, the Alpha Genome initiative from Google Deep Mind,
as well as the chan Zuckerberg initiative and the X Prize.

(01:17:34):
Now there is an X prize for health Span now
of one hundred and one million dollars that is on
offer and various.

Speaker 2 (01:17:43):
Teams are competing for it already.

Speaker 1 (01:17:46):
I hope that these initiatives do contribute significantly to progress
in the field right now, the magnitude is still not
as large as the magnitude of the NIH cust and
that's unfortunate. I do wish that all of this activity
and the NAH funded research had been happening in parallel,

(01:18:09):
but unfortunately that is not something within our control at
the present point. All that we can do is bring
up the harms. But Dan, would you like to have.

Speaker 8 (01:18:21):
A minor comment on what jose said. Yeah, I think it.
It remains to be seen how much influenced Jim o'nial have,
But I thank you for mentioning the MIT Tech Review article.
Definitely look at that. But the other thing is that

(01:18:47):
the new NIH director, Jay Baticharia, he is very interested
in what we might call metascience reformed, metascience inspired, and
reforms and changing policies at the NIH around how funding

(01:19:08):
is given out to support younger researchers, because they've been
finding the age of NIH grantees that's been going up
and up and up. And when he first came to NIH,
he gave a talk where he talked about a number
of a number of problems in science, like the reproducibility

(01:19:31):
crisis and other things. So, you know, so he actually
has a background in meta science himself. He actually years
ago did some research on NIH and looking at if
NIH was either at the state of the art or

(01:19:53):
actually lagging behind universities in terms of what researcher towards
study being in the internal h intramural research program. So
so I think I'm most excited about that, And they
have a lot of interesting ideas about changing how science

(01:20:14):
is funded. But overall, honestly, what I've been hearing, you know,
is fairly grim. Honestly, one thing I heard from Mark
Hammeline who's at our H, is that the people are
H are very worried that could get shut down. So

(01:20:36):
if that was if our H was shut down, that
would be devastating because as you know, we have John
Hibbert there and one or.

Speaker 9 (01:20:44):
Two other longevity folks.

Speaker 8 (01:20:46):
So I would just you know, if you hear anything
about our H being cut, I would I think that
would be a major thing we should try to fight
if possible.

Speaker 2 (01:20:58):
Yes, that is indeed troubling.

Speaker 8 (01:21:02):
And that's just all rumors, you know, I don't have
any definite information on that, but it's, uh, it just
seems like something they would do, uh, you know, just
just because because it's a by it was a binary thing,
and and they're trying to quote simplify and streamline and everything.
So yeah, we need to we need to have uh

(01:21:27):
we need to be on alert for for this sort
of things.

Speaker 1 (01:21:32):
Yes, cutting our pa H would be an even greater
travesty than what has transpired thus far. In my view,
arpa H was one of the most promising, if not
the most promising federal initiatives that could have made a
difference in antiaging research.

Speaker 8 (01:21:52):
And the interrector was actually fired uhr, Gene I forget
her name, Regina something she was, you know, among all
these different people who were fired. So the agency is
in a little bit of a disarray. And I've heard
that a lot of the staff who are contractors are
no longer there do the funding cuts and everything. So

(01:22:15):
it's it's very troubling.

Speaker 2 (01:22:18):
Yes.

Speaker 1 (01:22:19):
At Vitalist Bay about a month and a half ago,
there were two representatives from our pa H. One was
doctor Jean Abert, who was familiar to longtime attendees of
our Virtual Enlightenment salons because he was a guest of
ours in April of twenty twenty one.

Speaker 2 (01:22:38):
And then I moderated a panel with him at.

Speaker 1 (01:22:41):
Radfest in October of twenty twenty two, so you can
watch both of those sessions.

Speaker 2 (01:22:48):
He was there and he told me he was fairly.

Speaker 1 (01:22:51):
Optimistic at that point that the decision makers within the
Trump administration had sympathies for our pa H. But again
that was a month and a half ago. And then
at Vitalist Bay there was also Andrew Brack, who is
a program manager at ARPA H, and I essentially asked

(01:23:11):
him a question.

Speaker 2 (01:23:12):
I tried to be as.

Speaker 1 (01:23:14):
Non political as possible in the way I formulated that question,
but I formulated it in essence as a statement that
background stability is necessary in order to be able to
effectively make long term plans. How confident are you that

(01:23:34):
you will have that kind of background stability for a
five year time horizon so that you're planning over the
next five years can proceed essentially as you intended. But
he saw through my wording and he said, well, I'm
not going to comment on anything political, but urpa H
is fully aligned with the MAHA agenda because our research

(01:23:58):
is going to help make Americans health here. So he
phrased it in a bit more detail than that, but
that was the essence of the answer. I couldn't get
a gauge of how worried or concerned he was. I
think he was rather trying to kind of uh signal
to the powers that be that it shouldn't be cut

(01:24:23):
because it could be at least presented to align with
their goals.

Speaker 9 (01:24:28):
Right, Yeah, No, that's uh, that's interesting. I was I mean,
this is.

Speaker 8 (01:24:34):
This was sort of off the record, I suppose, but
I was spoken with, uh talking to Mark Ham.

Speaker 9 (01:24:40):
Align came aligne.

Speaker 8 (01:24:43):
And uh, yeah, it's it's very unclear what's what's going on.
But if yeah, there there there's a hope uh you
know that if if among some researchers that if they
can align their if they can brand their research properly
as being part of the MAHA movement whatever that is,

(01:25:06):
they can maintain their fundings. So I know, like a
lot of lung. I spoke with long COVID researcher who's
trying to rebrand their research now, and they're studying, like
you know, they're studying, you know, the MAHA agenda and

(01:25:27):
trying to rebrand so that that's.

Speaker 9 (01:25:33):
You know, supposedly the.

Speaker 8 (01:25:35):
MAHA is supposed to be about chronic diseases and things
like obesity, but they largely, I mean largely have been
looking at very niche, flashy issues like food colorings, food dies,

(01:25:56):
which you know, don't really have any effect on our
health as far as you know, all the gold standard
research says, and some of the some of the natural
dyes that they're proposing actually have been much less studied
than the artificial dyes. So so yeah, so it's uh,

(01:26:18):
it's very like uh, it's very uh like the topics
are are are kind of a lot, very like showing
topics like you know, mom, that are you know, designed too,
you know, uh went over you know. I don't really

(01:26:40):
know what they're doing, honestly, but they're not looking at them.

Speaker 9 (01:26:43):
I haven't seen much on.

Speaker 8 (01:26:44):
The big problems like obesity, cardi bassaard disease, those kind
of things.

Speaker 1 (01:26:52):
Yes, sometimes I don't think they know what they're doing.
I don't think they know coherently what their agenda is
and to oppose whatever they consider to be the scientific
establishment or the medical.

Speaker 8 (01:27:06):
Things there there as far as things therefore, it's it's
it's sort of a it's sort of a.

Speaker 9 (01:27:14):
It's sort of a very like uh like eyeball mix
of very contrab like low impact.

Speaker 8 (01:27:27):
Things that that are but but that are kind of controversial,
like food dyes and and floridation of water and stuff
like that.

Speaker 1 (01:27:39):
Yes, indeed, now, David, you have a few remarks to
share which are perhaps more hopeful.

Speaker 3 (01:27:48):
Well, let me tie back some of the discussion to
presentation at Dublin, which is the starting part for all
of this. One of the most inspiring slides of all
was shown by Alexander teitz Latser, who some of us know.
He's a German lawyer. He stood several times for the

(01:28:09):
European Parliament. He's a longtime member of the ISLA. He
gave a talk about why we should be advocating that
healthy longevity is recognized as a human right. But at
the very end he showed a picture of himself with
I thought an eighty year old woman. So she was
sitting there. Turned out that she was his grandmother and

(01:28:30):
she was one hundred and five years old, and she
looked to marketly healthy for one hundred and five year old.
So Alexander probably gets the prize for having the oldest
healthy relative amongst all the speakers as far as I know.
So that was encouraging. Now, already we had mentioned from
Jose that for his conference in Madrid last year he

(01:28:51):
was hoping to present to Maria Branyas, who was at
the time the world's oldest person one hundred and seventeen
and a half years old. Sadly, she died a few
days beforehand. It turns out that the oldest person in
the world today, as far as we can validate, is
actually living twenty miles away from where I am. Her
name is Edith Ethel catererm She's one hundred and fifteen

(01:29:15):
years old, so a relative youngster compared to Maria. She'll
be one hundred and sixteen in a a couple of
months time. So maybe the UK is doing some things right.
We'll see. But it's the first time for a long
long time that the oldest person in the world has
been in the UK. But actually, more seriously, the UK
is trying hard to do something right. We've had an

(01:29:37):
announcement by the government four days ago that there is
a new ten year plan for the NHS and this
ten year plan will have three components in it. This
was made by the UK's Chancellor, the UK's Secretary of
State for Health. Where's treating who himself is a cancer survivor.

(01:29:57):
He's been at the sharp end of the NHS in
his own life and by the Prime Minister, and they
basically said, we can't solve the money the problems of
healthcare just by spending more money doing more of the same.
There has to be three fundamental changes. The first is
from the hospital to the community and otherwise allow people
to be treated more locally rather than having to go

(01:30:19):
to big centralized hospitals. Secondly, moving from analog to digital
to hurry up and apply the best of AI and
the best of other digital solutions. But the third of
the three big transformations is the most promising. They're talking
seriously about changing it from being a sickness industry to
a prevention industry. And they're very open, they say, to

(01:30:41):
figuring out how they can do more prevention earlier. So
they should be interested to hear whatever Andrew Steele and
others bring them. But they should also be looking at
other presentations from Dublin, because some of the best presentations
in Dublin. I thought, we're also talking about what's happening
in Singapore. Singapore government has a recognized the crisis that

(01:31:05):
they have with more elderly people who are unwell, and
they have given lots of initiatives to try and improve
the health span rather than just the lifespan, so that
people live healthier for longer, and they are describing themselves
as the first engineer the blue zone. In other words,

(01:31:25):
they have longer lives, not just because of what has
happened historically and traditionally, but interventions are being put in place.
So it is my recommendation to the UK government and
elsewhere we should be learning from what's happening in Singapore.
Somebody said he thought there were two countries that were
doing particularly well in terms of engineering improvements to healthcare.

(01:31:49):
There was Singapore and the other wise. This is a
bit of a surprise to me, it was Denmark. And
the reason they thought Denmark was doing particularly well is
in part because of all their work being done on
by the group behind a r DD the annual conference there.
So I think we should be learning from each other

(01:32:10):
and in order to actually go forwards, governments are going
to have to set aside their nationalistic bias. Hey we're
the best, you know, we British, We've got the Mother
of Parliament. What can we learn from others? Well, actually
we have plenty we can learn from others. America first, well,
maybe America should be learning from Singapore and Denmark as well.
And with this kind of attitude, it's opened this in humility,

(01:32:32):
we can actually pick up the best practices from around
the world. So that's what I think should be happening.
What's happening in America now is let's say, an extraordinary experiment,
but hopefully people will realize, hey, maybe they should be
feeding in some of the insights from Singapore and Spain,
Madrid and Copenhagen and elsewhere too.

Speaker 1 (01:32:54):
Yes, indeed, I think it's important to learn from successes
and success full implementations anywhere in the world. Wherever something
is found to work, we should utilize it and hopefully
it will gain traction and many other jurisdictions as well.
I wanted to briefly mention my own presentation at Longevity

(01:33:18):
sum at Dublin. I will not go through it in entirety,
but I did want to note that I present it
on LV the game, which is the game where one
gets to play as a character seeking to reach longevity
Escape Velocity, and fortunately I do have a few pictures

(01:33:41):
of my presentation. The recording should be out later once
Longevity sum At Dublin publishes all of the talks on
its YouTube channel. But right now you see the screenshot
of one of the slow where I provide some background

(01:34:02):
as to the origins of Lev the game and how
the US Transhumanist Party came to acquire the rights to
develop it in twenty twenty and I developed an entirely
new set of mechanics and in game events.

Speaker 2 (01:34:21):
For the game.

Speaker 1 (01:34:22):
I transformed it into a turn based game with the
help of Euraisteren Vukotitch, whom I hired as the programmer,
and of course we held a Virtual Enlightenment Salon in
twenty twenty four in May of twenty twenty four to
demonstrate an earlier build, which is Build zero point six
of Lev the Game. But now we have a much

(01:34:45):
more current version which is Build zero point nine to one,
and it is available to download and play at Transhumanist
Dash Party dot org slash Lev Dash the Dash Game.
You have the ability to download it in one of
two archive formats ZIP and RAR, and you can also

(01:35:09):
if the archive formats don't work with your computer or
your laptop for whatever reason, download the files directly I've
made them available in a Google Drive folders. So either way,
if you have a PC, whether it's a Windows PC
or a Linux PC, please download the game, give it
a try yourself and see if you can get your

(01:35:30):
character to longevity Escape Velocity. I think my presentation was
very well received among the attendees, and I'm going to
also be presenting on LV the game at Radfest in
Las Vegas in just less than a week's time, so
I am definitely looking forward to that. Jose, would you

(01:35:52):
like to say a few remarks?

Speaker 4 (01:35:55):
Well, great, great, I want to practice with your game
on congres, gratulations on your presentation, and again it's good
that we are going to meet in Las Vegas. I'm
flying on Tuesday, and it is important to get different audiences,
different publics, so that is why I was so happy

(01:36:16):
to see David s VN and you Gennadi in Dublin
and see you also now soon in Las Vegas and
welcome to Madrid as well. We need to have more
and more until longevity becomes a fact of life. That
is my goal and that is why we have to
do it. We have to do it. That is why

(01:36:38):
when I didn't like and don't take it personally your comment,
which is Andrew Stills comments about one cup of coffee
a day. You know, John Fisher and Kennedy had a great,
a great phrase. Well he had Benny like video these
Uh sometime politicians.

Speaker 5 (01:36:55):
Churchill is even better.

Speaker 4 (01:36:56):
But John Fisher and Kennedy said, Uh, don't ask America
what can it do for you, ask what you can
do for America. So my phrase is, don't ask what
longevity can you for you as what you can do
for longevity, and that is putting the money of your
cup of coffee. And don't blaming our American friends or

(01:37:20):
US friends because they are doing better than in Europe
in terms of funding for longevity research, even though which
is a tragedy. This is the real tragedy that the
usay longevity expectancy is so low, especially after putting almost
twenty percent of the gross domestic product both on public

(01:37:42):
and private health. I mean, this is horrible with all
that money that the outcome is so poor. And let
me just go back to the blue zones, because David
was talking about the blue zones and indeed Singapore declared
itself as a Bluestone two point zero, which I think
is interesting experiment, and this is what we want to

(01:38:02):
do in Madrid because the original Blue Zones are just
a marketing plot by Dan Bergner when he was at
National Geographic and what he wrote, you know, the five
Blue Zones traditional blue zones Sardinia in Italy, Ikaria in Greece,
Okinagua in Japan, Nicoia Peninsula in Costa Rica, and Lo

(01:38:29):
Ma Linda in California. All of them have lower life
respectancies than Madrid, so how can they be blue zones?
And these are tiny places, you know, like Ikaria, it
carries a statistical mistake. You know, Madrid has over eight
million people with a longer life respectancy than I Carria, Sardinia, Okinawa,

(01:38:51):
Loma Linda.

Speaker 5 (01:38:53):
But just one more thing about this being marketing.

Speaker 4 (01:38:55):
I was a few months ago in Miami, and maybe
some of you know that the Seventh Day Adventist Church
both the rights of the Blue Zones. They paid I
don't know if two three million dollars to Dan Werner
for the idea of the concept. And now they are
building a huge, a huge center in downtown Miami which

(01:39:20):
I visited. It's called the Blue Zone Center. And again
it was just marketing if you really want a blue
Zone center, come to Madrid.

Speaker 1 (01:39:31):
All right, thank you, Jose, And you and I had
a conversation as to what potential hypotheses could explain the
greater longevity of people in Madrid. I had a hypothesis,
but it ended up being incorrect. So I would be
interested in more studies being done as to why the

(01:39:52):
life expectancy in Madrid is relatively so high over eighty
six years.

Speaker 2 (01:39:57):
That is impressive for a city, especially.

Speaker 4 (01:40:00):
Yes, for for a city so big. But again we
will show the answer. That is why we are commissioning
not one or two, but three studies by the consulting
company McKinsey, by the Royal Academy of Medicine of Spain
and by the National Science Foundation of Spain. So I
hope one of those three will find out the resource

(01:40:22):
that do have to do something with the points of
the blue estones. I repeat, Mediterranean diet, exercise familiar relations
and as the French say, Juan de Vivra, you know
the joy to be alive, which is what we want
to try exactly.

Speaker 7 (01:40:41):
And you so say, are making them live alone? Enthusiastic?

Speaker 1 (01:40:53):
Yes, yes, Hose, you are definitely an exemplar of that.
So thank you for or being a role model to
all those who seek to take joy in life. And
I also wanted to bring up three comments from David Wood.
First of all, he says Google wrote to recovery the

(01:41:15):
government's twenty twenty five mandate to NHS England to find
more details of the UK government initiative that he mentioned.
Another recommendation from David one of the best AI tools
to improve scientific discovery and his view as future House
funded by, among other sources.

Speaker 2 (01:41:34):
Eric Schmidt, who used to be the CEO of Google.

Speaker 1 (01:41:38):
And finally, in the spirit of ask not what your
country can do for you, but ask what you can
do for your country, he would recommend the book Moral
Ambition by Rutger Bregman. So please check out those resources.
And Sven, would you like to say anymore, I see
you've got some slides pulled up.

Speaker 7 (01:42:00):
Yes, exactly, thank you.

Speaker 6 (01:42:01):
So first of all I have to say Mia Kulpa
to She'll say, because he's absolutely right that Belgium is
not doing anything in this area. Some of the European
countries are doing something. In Germany, you have the Max
Planck Institute. In the Netlands, you have the European Research
Institute for the Biology of Aging. Every pathok short, but

(01:42:23):
in Belgium we don't have anything. In fact, my love
and another lave have on all the aging work, so
we are even losing it. There is less aging work
being done in Belgium now than a few years ago,
and I would like to see a European Institute of
Aging being established, but let's hope that comes from day.

(01:42:47):
I also can testify that alex bandmother is indeed doing
so well, at least several years ago. I was lucky
enough to meet her and she lives at home with
her doctor, who herself is an old in her eighties
by now, still able to do everything and is fully
clear in mind.

Speaker 7 (01:43:07):
But what I really wanted to talk about is the
AI discussion. I had some comments to make on that.

Speaker 6 (01:43:14):
So I think we already have developed automated tools. As
Genad was saying, we need some type of side box
type of tool that will test the research, and in fact,
well we already have fully automated I can show here

(01:43:36):
how a fully automated LOP looks like in the pharmaceutical industry. Now,
these all labs that don't use AI to do experiments.
It's humans coming up with experiments and the robots doing it. However,
small scale integration systems have already been built where AI
comes up with hypothesis and then you have a fully

(01:43:58):
automated LAP that tests the hypothesis that the AI comes
up with, and then the findings from that gets funneled
back into the EI, who comes up with new hypotheses
that then that get tested.

Speaker 7 (01:44:11):
But there are challenges in all of this.

Speaker 6 (01:44:16):
So the challenges that we're also pointed out at a
conference is the lack of data. And also there is
no incentive for people to build a large data to
build the library of all the data that exists, because
who is.

Speaker 7 (01:44:32):
Going to fund that work. U and the llms were.

Speaker 6 (01:44:36):
Trained on millions of books, but we don't have that
type of tentalized access to scientific data.

Speaker 2 (01:44:42):
Now.

Speaker 6 (01:44:43):
A problem with the scientific data is also it's very heterogeneous.
You have texts data obviously, you have tables, you have graphs,
you have histological sections, you have Western blocks. So you
have all of these different data which will need different
types of training to be used for AI to be

(01:45:05):
analyzing those, and of course, as we as pointed out,
you still will need to do experiments with all that data.
So in my opinion, AI is a tool just like
all the scientific tools. It's not replacing the existing tools,
but it's adding to the existing tools. And yes, I'm
very hopeful that AI will accelerate the research just like

(01:45:29):
every other scientific tool. Think about christ pass has also
accelerated our scientific research. Our aspect has also accelerated our research.
Every one of these scientific tools accelerates research. In fact,
the best way to accelerate scientific research is to build
a new tool, because tools generally bring in a lot

(01:45:49):
of new knowledge.

Speaker 7 (01:45:51):
That was my remarks.

Speaker 1 (01:45:53):
Yes, thank you very much then, and I completely agree.
AI is a new tool or a suite of tools,
and it will definitely help to accelerate the pace of research.
But the best way in which it will help will
be in addition to existing tools and the efforts of
human scientists as well. Though the AI operated lab that

(01:46:17):
you showed as quite impressive. So I live in northern
Nevada and in Reno, Nevada, there is a facility operated
by doctor Bill Andrews. His company Sierra Sciences is leasing
about ten thousand square foot ten thousand square foot building

(01:46:37):
with lab space, and prior to the pandemic. He would
give people tours of the lab space, including the assay
robots that he had, which also could essentially test several
one hundred samples a minute.

Speaker 2 (01:46:55):
And these particular.

Speaker 1 (01:46:58):
Robots that you showed are even more advanced than what
Bill Andrews demonstrated. His robots are probably definitely more than
a decade old, probably around two decades old based on
my knowledge of when he had essentially peak funding to

(01:47:19):
acquire those robots. But yes, some functions of lab experiments,
such as taking essays of various substances, can be automated
and indeed scaled up massively through this kind of technology.
And if AI can supply certain hypotheses as a test

(01:47:41):
these substances in this manner, these robots could at least
in principle, implement those tests. So we have about six
minutes left in our Virtual Enlightenment Salon today. I would
like to ask art Ramon if he has as any
questions or comments based on what has been discussed or

(01:48:03):
anything else he's curious about in regard to longevity summing Dublin.

Speaker 11 (01:48:10):
Not specifically with the summit, but just from what I
remember hearing. This one diet YouTube is an influencer Xcia Guy.
He says that the government sees the population like the
super organism, just a GD producing super organism, and reminds

(01:48:32):
me like early on during COVID, how they predicted there
would be like two point two million deaths and they
had to throttle that death by the lockdowns. Well, with
you know, the upcoming Java apocalypse, maybe they want to
increase that death rate because you're just going to have

(01:48:54):
an excess number of people who aren't going to be
producing much to say, kind of cynical, I don't, but
that's what comes to mind when I see like the
funding cuts in ih It's just they really don't care.

Speaker 5 (01:49:13):
They kind of need that.

Speaker 11 (01:49:14):
Turnover the super organism. And you know, maybe that the
funding will come back one day, but in the short term,
you know, with the slow moving World war, they have
other things to concentrate on. But hopefully, you know, other
countries could pick up the slack, you know, the European
Union and like I said that, those Blue zones, hopefully

(01:49:38):
they can pick up the slack while you know the
US drops the ball.

Speaker 1 (01:49:43):
Yes, fortunately, and I'll say this fortunately the power elites,
especially in the United States, are too uncoordinated and too
short sighted in my view, to be the kinds of
systems thinkers that they would need to be in order
to be deliberately seeking the reduction of the human population

(01:50:07):
in the manner you describe. So I'm a bit more
optimistic in that I don't think they're smart enough to
even come up with that idea. I think they are
essentially pursuing very short term'sed agendas, appealing to their base,
and really acting in almost complete ignorance of what they're doing.

(01:50:32):
So they're cutting so thoughtlessly because really they haven't thought
about the implications of what they're cutting, and they haven't
thought about how it would affect their longevity personally, because
if a power elead were to engage in the kind
of nefarious scheme you describe, at least they would have
protected some of the longevity research for themselves.

Speaker 2 (01:50:54):
But they're not even doing that.

Speaker 1 (01:50:56):
So I would say, I'm not going to attribute to
malice something that can be explained by incompetence or, as
jose would put it, human stupidity.

Speaker 2 (01:51:08):
But thank you for your observation there.

Speaker 1 (01:51:13):
I think it's also important to note, and this was
observed previously, that there are concerns about who will access
these advances, and that's a worthwhile discussion to have. Mike

(01:51:35):
Lazine pointed this out in some of his comments. He wrote,
all of these different types of technology sound very expensive.
How many people have healthcare plans that can cover these
procedures or is at all out of pocket? And David
Wood wrote, this is something we should come back to

(01:51:56):
because it's a very important question. So, David, we have
about two minutes left. I wonder if you could provide
some brief points in response to Mike, and then we
will conclude.

Speaker 3 (01:52:08):
So we've discussed a bit of this already. This is
when I talked about, well we can scale things up.
We have government support, government guarantees for using the products
at scale. But another thing that has already been mentioned here,
and I want to support what Jose Acodero was saying,
which is that there can be prizes which can galvanize

(01:52:29):
lots of innovative news solutions. So there has recently been
a selection of semi finalists, there were many more companies
and organizations or teams that have produced high quality research
then had been theared. So this is very encouraging. But
another thing that's very encouraging about Xprize. I want to

(01:52:51):
give a shout out to Alberto Aparicio because he gave
a very nice presentation at Dublin. It's worth checking out
once the videos are available. He pointed out that the
way the Exprize for health Span had been set up,
it actually met a lot of the possible ethical concerns
that some people might have had. They might have thought, well,
are these people really informed of what's going on? He

(01:53:15):
had raised about seven different possible ethical concerns and he
argued that this had been very well designed and so
this is another reason to expect that the Exprize health
Span is going to have a big impact. And one
final reference to one more talk is the idea from
Keith Camito, who is the president of the Lifespan and

(01:53:39):
Research Institute. He gave a very interesting talk which he
basically talked a lot about at Disney narrative which had
come from an ancient Indonesian narrative about Muawi, in which
he related some of our present day concerns about slowing
down aging to an ancient Indonesian idea about slowing down

(01:54:02):
the sun. And Key's bigger argument is, you know, we
need to explore different ways of talking about what we're
doing that might resonate with ancient cultural traditions or other
ways to make people inspired. And so Keith is saying,
let's be creative in the narratives as well as pursuing
the science. And this matches my own view that what

(01:54:23):
we're doing here, it's not just a bioengineering, it is
narrative engineering and also community engineering. And it's by doing
these three things well and that goes way beyond technology,
that we can bring down the costs for everybody and
get more people united together working on these problems rather

(01:54:45):
than being distracted into all the kind of terrible things
that most of us do often get distracted into.

Speaker 1 (01:54:52):
Yes, thank you very much David for those inspiring words.
And indeed we need all of these forms of engineering
so that we can all live long and prosper

All Episodes

Episode Transcript

Popular Podcasts

On Purpose with Jay Shetty

Stuff You Should Know

Dateline NBC

.css-15opob5{left:0;position:absolute;top:0.8rem;} All Episodes

.css-14f5ked{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:2;overflow:hidden;}Longevity Summit Dublin 2025

Episode Transcript

Popular Podcasts

.css-r6mb8g{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:1;overflow:hidden;}On Purpose with Jay Shetty

Stuff You Should Know

Dateline NBC

All Episodes

Longevity Summit Dublin 2025

On Purpose with Jay Shetty